Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors

Christian Kollmannsberger, Herbert I. Hurwitz, Lyudmila Bazhenova, Byoung Chul Cho, David S. Hong, Keunchil Park, Karen L. Reckamp, Sunil Sharma, Hirak Der‐Torossian, James G. Christensen, Demiana Faltaos, Diane Potvin, Vanessa Tassell, Richard C. Chao, Geoffrey I. Shapiro